
Overton Withdrawal Extends FDA Leadership Vacuum for Drug Sponsors
Key Takeaways
- Withdrawal occurred one day before a closely divided HELP Committee vote, reflecting fragile support after midterm losses and uncertainty among key Republicans, including then-Chair Bill Cassidy.
- Vaccine-related backlash centered on her visible support for reducing federally recommended childhood vaccines and splitting MMR into separate injections, unsettling medical groups and career FDA staff.
Trump withdraws FDA commissioner nominee Heidi Overton, extending a leadership gap that leaves review and launch timelines uncertain for sponsors.
President Donald Trump has withdrawn Heidi Overton’s nomination to serve as commissioner of the FDA.1 According to 3 people familiar with the matter who spoke to Reuters, the cause was her lacking in enough support from Congress. The withdrawal came 1 day before the Senate Health, Education, Labor and Pensions (HELP) Committee was due to vote on her nomination. Republicans held only a one-vote advantage on the committee, so a single Republican defection could have defeated her.
Two of the sources told Reuters that the White House is weighing Sen. Roger Marshall of Kansas as a replacement nominee.¹ Marshall is a former obstetrician who recently lost his reelection bid. FDA Deputy Commissioner for Food Kyle Diamantas continues to serve as acting commissioner.
How Did Overton’s Nomination Unravel?
The White House
Some Trump officials began to doubt her support after Republicans lost control of both the House of Representatives and the Senate in this month’s midterm elections.¹ Several HELP Committee members lost their reelection bids, including outgoing Chairman Bill Cassidy, a Louisiana Republican and physician, as well as Susan Collins and Marshall. Cassidy had said he remained undecided. He had previously criticized Overton’s involvement in the administration’s efforts to roll back childhood vaccination.
Overton faced opposition from several directions:
- Vaccines: In August, she appeared with Trump at an event promoting an executive order.1 The order called for fewer federally recommended childhood vaccinations and for splitting the measles, mumps, and rubella shot into 3 separate jabs. According to people familiar with the conversations, her support of that order unnerved several medical groups and career FDA officials.
- Mifepristone: Democrats criticized her stance on the abortion pill.1 The FDA is currently conducting a safety review of mifepristone and has said it will conclude by March 2027.
- Vaping: A nonpartisan advocacy group, Health in Office, launched a campaign against her nomination.1 At her September confirmation hearing, she had defended FDA’s May authorization of fruit-flavored vapes.
Why Does This Matter?
The withdrawal prolongs a leadership vacuum at an agency that has
That instability is already affecting regulatory planning.1 Many of Makary’s acceleration initiatives did not go through formal rulemaking, which left them open to reversal. One of these, the
A new nominee will go before a Senate that Republicans will no longer control.1 Until a commissioner is confirmed, sponsors face continued uncertainty over review timelines, guidance priorities, and whether recently introduced programs will survive. For quality and regulatory teams, submission planning may need to assume established review pathways until the agency’s direction becomes clearer.
References
- Bogage J, Abutaleb Y. Reuters. Trump withdraws Heidi Overton as nominee to lead Food and Drug Administration, sources say. November 18, 2026. Accessed November 18, 2026.
https://www.reuters.com/legal/litigation/trump-withdraws-heidi-overton-nominee-lead-food-drug-administration-sources-say-2026-11-18/ reuters - Jones A. Trump picks White House aide Dr. Heidi Overton for top FDA job. ABC News. August 19, 2026. Accessed November 18, 2026.
https://abcnews.com/Politics/trump-picks-dr-heidi-overton-top-fda-job/story?id=135777387 - Haigney S. Regulatory roundup—August 2026. PharmTech. Aug. 31, 2026. Accessed November 18, 2026.
https://www.pharmtech.com/view/regulatory-roundup-august-2026 - Zubulake Z. Signs point to FDA shelving priority voucher pilot, stalling fast-track drug reviews. PharmTech. Nov. 12, 2026. Accessed November 18, 2026.
https://pharmtech.com/view/fda-shelves-priority-voucher-pilot-stalling-fast-track-drug-reviews
Related to this article









